Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jul 23, 2009


Title: Methods and Compositions for Treating Keratin Hyperproliferative Disorders

Number: 20090181908

Filed: Dec. 29, 2006

Lead Inventor: Roger Kaspar, TransDerm

The patent application, its abstract states, claims "a method for [treating] keratin hyperproliferation disorders such as corns, calluses, or keratosis pilaris by administering to a subject experiencing the disorder a therapeutically effective amount of an RNA sequence which inhibits expression of a gene encoding for a keratin selected from the group consisting of K6a, K6b, K16, K17, and combinations thereof."

The application specifically claims the use of an siRNA to achieve a therapeutic response.

Title: Specific GRP78 Expression-Inhibition RNAi Sequence, Medicine Thereof, and Method Thereof


July 17, 2008

Lead Inventor: Ann Joy Cheng, Sinorica

The invention, the patent application's abstract states, comprises the "RNAi sequence 5'-AAGGATGGTTAATGATGCTGAGAA-3', [which is] complementary to GRP78 [and] forms a special hairpin structure inside cancer cells to specifically and effectively inhibit GRP78 expression and then inhibit the canceration process, including the growth, migration, invasion, and metastasis of cancer."

Title: siRNA Targeting Phosphatases

Number: 20090182134

Filed: Oct. 24, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to phosphatases."

Title: Small Internally Segmented Interfering RNA

Number: 20090182136

Filed: March 23, 2007 PCT Filed: March 23, 2007

Lead Inventor: Jesper Wengel, RiboTask

The invention is "directed to pharmaceutical and therapeutic compositions which comprise RNA complexes comprising an antisense strand and a discontinued passenger strand capable of regulating gene expression," the patent application's abstract states. "The use of a discontinued passenger strand reduces off-target effects of the RNA complexes and also has other advantages."